Literature DB >> 33574444

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells.

Tara Al Zubaidi1,2, O H Fiete Gehrisch1,2, Marie-Michelle Genois3, Qi Liu1,4, Shan Lu1,5, Jong Kung1, Yunhe Xie1, Jan Schuemann1, Hsiao-Ming Lu1, Aaron N Hata3, Lee Zou3, Kerstin Borgmann2, Henning Willers6.   

Abstract

Mutant KRAS is a common tumor driver and frequently confers resistance to anti-cancer treatments such as radiation. DNA replication stress in these tumors may constitute a therapeutic liability but is poorly understood. Here, using single-molecule DNA fiber analysis, we first characterized baseline replication stress in a panel of unperturbed isogenic and non-isogenic cancer cell lines. Correlating with the observed enhanced replication stress we found increased levels of cytosolic double-stranded DNA in KRAS mutant compared to wild-type cells. Yet, despite this phenotype replication stress-inducing agents failed to selectively impact KRAS mutant cells, which were protected by CHK1. Similarly, most exogenous stressors studied did not differentially augment cytosolic DNA accumulation in KRAS mutant compared to wild-type cells. However, we found that proton radiation was able to slow fork progression and preferentially induce fork stalling in KRAS mutant cells. Proton treatment also partly reversed the radioresistance associated with mutant KRAS. The cellular effects of protons in the presence of KRAS mutation clearly contrasted that of other drugs affecting replication, highlighting the unique nature of the underlying DNA damage caused by protons. Taken together, our findings provide insight into the replication stress response associated with mutated KRAS, which may ultimately yield novel therapeutic opportunities.

Entities:  

Year:  2021        PMID: 33574444     DOI: 10.1038/s41598-021-83142-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  44 in total

Review 1.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

2.  Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Authors:  Kristin Gurtner; Zofia Kryzmien; Lydia Koi; Meng Wang; Cyril H Benes; Sandra Hering; Henning Willers; Michael Baumann; Mechthild Krause
Journal:  Int J Cancer       Date:  2019-08-19       Impact factor: 7.396

3.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Authors:  H Blons; J F Emile; K Le Malicot; C Julié; A Zaanan; J Tabernero; E Mini; G Folprecht; J L Van Laethem; J Thaler; J Bridgewater; L Nørgård-Petersen; E Van Cutsem; C Lepage; M A Zawadi; R Salazar; P Laurent-Puig; J Taieb
Journal:  Ann Oncol       Date:  2014-10-06       Impact factor: 32.976

4.  Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.

Authors:  E J Bernhard; E J Stanbridge; S Gupta; A K Gupta; D Soto; V J Bakanauskas; G J Cerniglia; R J Muschel; W G McKenna
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Authors:  Meng Wang; Jing Han; Lynnette Marcar; Josh Black; Qi Liu; Xiangyong Li; Kshithija Nagulapalli; Lecia V Sequist; Raymond H Mak; Cyril H Benes; Theodore S Hong; Kristin Gurtner; Mechthild Krause; Michael Baumann; Jing X Kang; Johnathan R Whetstine; Henning Willers
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

6.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

7.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Authors:  Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.

Authors:  Shiraj Sen; Funda Meric-Bernstam; David S Hong; Kenneth R Hess; Vivek Subbiah
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

9.  KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.

Authors:  Oliver S Chow; Deborah Kuk; Metin Keskin; J Joshua Smith; Niedzica Camacho; Raphael Pelossof; Chin-Tung Chen; Zhenbin Chen; Karin Avila; Martin R Weiser; Michael F Berger; Sujata Patil; Emily Bergsland; Julio Garcia-Aguilar
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

10.  Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Authors:  Keith A Cengel; K Rahn Voong; Sanjay Chandrasekaran; Laurence Maggiorella; Thomas B Brunner; Eric Stanbridge; Gary D Kao; W Gillies McKenna; Eric J Bernhard
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

View more
  5 in total

Review 1.  Targeting replication stress in cancer therapy.

Authors:  Alexandre André B A da Costa; Dipanjan Chowdhury; Geoffrey I Shapiro; Alan D D'Andrea; Panagiotis A Konstantinopoulos
Journal:  Nat Rev Drug Discov       Date:  2022-10-06       Impact factor: 112.288

Review 2.  Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.

Authors:  May Elbanna; Nayela N Chowdhury; Ryan Rhome; Melissa L Fishel
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

3.  RAS-mediated tumor stress adaptation and the targeting opportunities it presents.

Authors:  Alexandra Redding; Andrew E Aplin; Elda Grabocka
Journal:  Dis Model Mech       Date:  2022-02-11       Impact factor: 5.758

Review 4.  Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.

Authors:  Anthony Turpin; Cindy Neuzillet; Elise Colle; Nelson Dusetti; Rémy Nicolle; Jérôme Cros; Louis de Mestier; Jean-Baptiste Bachet; Pascal Hammel
Journal:  Ther Adv Med Oncol       Date:  2022-09-06       Impact factor: 5.485

5.  Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.

Authors:  Linlin Yang; Changxian Shen; Adriana Estrada-Bernal; Ryan Robb; Moumita Chatterjee; Nikhil Sebastian; Amy Webb; Xiaokui Mo; Wei Chen; Sunil Krishnan; Terence M Williams
Journal:  Nucleic Acids Res       Date:  2021-11-08       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.